Skip to main content

Table 3 Comparison of clinical and biological characteristics between acute myeloid leukemia (AML) patients, with or without NPM1 and FLT3-ITD mutations

From: Acute myeloid leukemia and transcription factors: role of erythroid Krüppel-like factor (EKLF)

 

Mutated NPM1

WT NPM1

p

ITD FLT3

WT FLT3

p

Gender of patients (male/female)

7/2

19/16

0.201

5/3

21/5

0.828

Age/years (median)

56.0

50.6

0.560

52.0

52.3

0.975

Status Performance/ECOG

3/3/1/2

9/7/15/4

0.347

2/4/1/1

10/6/15/5

0.190

WBC count,x109/L (median)

109.60

17.14

0.001

80.04

26.28

0.051

Hemoglobin, g/dL (median)

9.59

9.35

0.724

9.46

9.39

0.893

Platelet, count, x109/L (median)

58.0

94.4

0.332

60.87

93.64

0.142

Percentage of Blasts in PB (median)

79.7

33.1

<0.001

66.38

27.78

0.013

Percentage of Blasts in BM (median)

91.2

63.5

<0.001

80.29

66.69

0.132

M2 vs. non-M2 FAB

1/8

8/27

0.436

3/5

6/30

0.186

M3 vs. non-M3 FAB

3/6

4/31

0.109

1/7

6/30

0.771

M5 vs. non-M5 FAB

3/6

4/31

0.109

1/7

6/30

0.771

FAB Type

1/1/1/0/3/0/0/02/1

3/8/4/1/4/2/1/9/0/0

0.053

1/3/0/0/1/0/0/1/1/1/8

3/6/5/1/6/2/1/8/1/0

0.420

WHO Type

1/0/0/8

7/11/12/12

0.049

1/2/0/5

7/9/2/15

0.770

Primary/Secondary LMA

9/0

25/10

0.068

8/0

26/10

0.090

Cytogenetic (MRC)

1/7/1

8/18/4

0.579

1/7/0

8/18/5

0.267

Cr 7 Alterations (yes/no)

0/9

4/26

0.248

0/8

4/27

0.284

Cr 5 Alterations (yes/no)

1/8

2/28

0.661

1/7

2/29

0.567

Cr 11 Alterations (yes/no)

2/7

5/25

0.703

2/6

5/25

0.560

CD34 Blasts (yes/no)

2/7

20/15

0.062

4/5

18/17

0.709

CD117 Blasts (yes/no)

7/2

22/13

0.400

8/1

21/14

0.103

CD15 Blasts (yes/no)

7/2

12/20

0.032

6/3

13/19

0.166

CD11B Blasts (yes/no)

4/5

5/25

0.083

2/7

7/23

0.945

CD11C Blasts (yes/no)

2/1

6/2

0.782

2/2

6/1

0.201

CD133 Blasts (yes/no)

2/3

12/16

0.905

2/3

12/16

0.905

CD123 Blasts (yes/no)

2/3

5/18

0.393

2/2

5/19

0.212

HLA DR + BLasts (yes/no)

3/6

19/18

0.408

4/5

18/9

0.236

CD56 Blasts (yes/no)

3/6

19/18

0.048

4/5

18/9

0.236

T-cell markers BLast (yes/no)

1/6

4/13

0.612

2/6

3/13

0.722

Erythroblasts BM

0/4/1

2/8/12

0.312

0/4/3

2/8/10

0.271

Gata-1 Expression (yes/no)

4/5

17/18

0.825

2/6

17/19

0.155

Gata-2 Expression (yes/no)

5/4

17/18

0.709

4/4

18/18

1

EKLF Expression (yes/no)

3/6

18/17

0.332

3/5

18/18

0.522

cMPL Expression (yes/no)

3/6

17/18

0.413

2/6

18/18

0.199

Gata-1 (Median Expression)*

0.127

5.187

0.615

0.107

5.051

0.639

Gata-2 (Median Expression)*

568.23

1273.38

0.759

5000.50

268.84

0.375

EKLF (Median Expression)*

0.0345

23.62

0.593

2.143

22.5

0.660

cMPL (Median Expression)*

3.61

7.01

0.608

4.258

6.768

0.639

  1. Nucleophosmin (NPM1) and FMS-related tyrosine kinase 3 (FLT3) genes. PS, Performance Status. WBC, white blood cell. FAB indicates French American British classification [19] and WHO indicates World Health Organization classification [20]. MRC, cytogenetic classification of Medical Research Cancer [21]. GATA binding protein 1 (GATA1), GATA binding protein 2 (GATA2), Erythroid Krüppel-like Factor (EKLF) and Mieloproliferative Leukemia virus oncogen homology (c-MPL). * All expression ratios are given as 100x target gene/GUS.
Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us